Structural mechanism underpinning cross-reactivity of a CD8+ T-cell clone that recognises a peptide derived from human telomerase reverse transcriptase by Cole, David K. et al.
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
Original citation: 
Cole, David K., van den Berg, Hugo A., Lloyd, Angharad, Crowther, Michael D., Beck, Konrad, 
Ekeruche-Makinde, Julia, Miles, John J., Bulek, Anna M., Dolton, Garry, Schauenburg, Andrea 
J., Wall, Aaron, Fuller, Anna, Clement, Mathew, Laugel, Bruno, Rizkallah, Pierre J., 
Wooldridge, Linda and Sewell, Andrew K.. (2016) Structural mechanism underpinning cross-
reactivity of a CD8+ T-cell clone that recognises a peptide derived from human telomerase 
reverse transcriptase. Journal of Biological Chemistry. doi: 10.1074/jbc.M116.741603  
 
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/84312     
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions. Copyright © 
and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners. To the extent reasonable and practicable the 
material made available in WRAP has been checked for eligibility before being made 
available. 
 
Copies of full items can be used for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge. Provided that the authors, title and full 
bibliographic details are credited, a hyperlink and/or URL is given for the original metadata 
page and the content is not changed in any way. 
 
Publisher’s statement: 
This research was originally published in Journal of Biological Chemistry.  
 
Cole, David K., van den Berg, Hugo A., Lloyd, Angharad, Crowther, Michael D., Beck, Konrad, 
Ekeruche-Makinde, Julia, Miles, John J., Bulek, Anna M., Dolton, Garry, Schauenburg, Andrea 
J., Wall, Aaron, Fuller, Anna, Clement, Mathew, Laugel, Bruno, Rizkallah, Pierre J., 
Wooldridge, Linda and Sewell, Andrew K.. (2016) Structural mechanism underpinning cross-
reactivity of a CD8+ T-cell clone that recognises a peptide derived from human telomerase 
reverse transcriptase. Journal of Biological Chemistry.  doi: 10.1074/jbc.M116.741603  
 
© the American Society for Biochemistry and Molecular Biology. 
 
A note on versions: 
The version presented here may differ from the published version or, version of record, if 
you wish to cite this item you are advised to consult the publisher’s version. Please see the 
‘permanent WRAP URL’ above for details on accessing the published version and note that 
access may require a subscription. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk 
 
1	  	  
Structural mechanism underpinning peptide cross-reactivity of a human telomerase reverse 
transcriptase reactive CD8+ T-cell clone 
 
 
David K. Cole1, Hugo A. van den Berg2, Angharad Lloyd1, Michael D. Crowther1, Konrad 
Beck3, Julia Ekeruche-Makinde1, John J. Miles1,4, Anna M. Bulek1, Garry Dolton1, Andrea J. 
Schauenburg1, Aaron Wall1, Anna Fuller1, Mathew Clement1, Bruno Laugel1, Pierre J. 
Rizkallah1, Linda Wooldridge5* and Andrew K. Sewell1* 
 
 
1Division of Infection and Immunity and Systems Immunity Research Institute, Cardiff University 
School of Medicine, Heath Park, Cardiff, CF14 4XN, UK; 2Mathematics Institute, University of 
Warwick, Coventry CV4 7AL, UK.	  3Cardiff University School of Dentistry, Heath Park, Cardiff, 
CF14 4XN, UK. 4QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia, 4029. 
5Faculty of Health Sciences, University of Bristol, Bristol BS8 1TD, UK. 
*These authors contributed equally to this study 
 
Running title: Structural basis of T-cell cross-reactivity 
 
Correspondence: Dr David K. Cole, Cardiff University School of Medicine, UK, E-mail: 
coledk@cf.ac.uk, or Prof Andrew Sewell, Cardiff University School of Medicine, UK, E-mail: 
sewellak@cf.ac.uk. 
 
Keywords: CD8+ T-cells, T-cell receptor (TCR), peptide-major histocompatibility complex (pMHC), 
T-cell degeneracy, telomerase, surface plasmon resonance, X-ray crystallography. 
 
ABSTRACT 
T-cell cross-reactivity is essential for 
effective immune surveillance, but has also 
been implicated as a pathway to 
autoimmunity. Previous studies have 
demonstrated that T-cell receptors (TCRs) 
that focus on a minimal motif within the 
peptide are able to facilitate a high level of 
T-cell cross-reactivity. However, the 
structural database shows that most TCRs do 
not utilize this mode of antigen binding. To 
further explore the structural features that 
allow the clonally expressed TCR to 
functionally engage with multiple peptide-
major histocompatibility complexes (pMHCs), 
we examined the ILA1 CD8+ T-cell clone that 
responds to a peptide sequence derived from 
human telomerase reverse transcriptase 
(hTERT). The ILA1 TCR contacted its 
pMHC with a broad peptide-binding 
footprint encompassing spatially distant 
peptide residues. Despite the lack of a 
focused TCR-peptide binding mode, the 
ILA1 T-cell clone was still cross-reactive. 
Overall, the mode of binding correlated well 
with the level of degeneracy at different 
peptide positions. Thus, the ILA1 TCR was 
less tolerant of changes at peptide residues 
that were at, or adjacent to, key contact sites. 
This study provides new insights into the 
molecular mechanisms that control T-cell 
cross-reactivity, with important implications 
for pathogen surveillance, autoimmunity and 
transplant rejection. 
 
Recognition of peptide-major 
histocompatibility complexes (pMHCs) by the 
clonally expressed αβ T-cell antigen receptor 
(TCR) mediates T-cell immunity. Although 
TCRs generally interact with pMHC via a 
conserved binding mode, with the TCRα chain 
positioned over the MHCα1 domain and the 
TCRβ chain over the MHCα2 domain, the TCR 
complementarity determining region (CDR) 
loops can use a variety of mechanisms to probe 
both the MHC surface and bound peptide (1). 
This flexible binding probably mediates the 
ability of a single TCR to interact productively 
with a large range of different epitopes (2–6). 
Thus, TCR degeneracy enables the circa 25 
million distinct TCR clonotypes expressed by an 
individual host (7) to have the potential to 
recognise the entire theoretical peptide universe 
that could be presented by MHC (2, 8), 
minimising the likelihood of pathogens escaping 
immune surveillance. Given the highly diverse 
number of TCR-pMHC binding modes seen to 
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date, it is reasonable to predict that different 
TCRs will exhibit distinct levels of cross-
reactivity, depending on the chemical 
characteristics of their CDR loops and how they 
interact with pMHC. Such distinctions could 
determine whether certain TCRs are more likely 
to offer sufficient protection against hyper-
variable pathogens, such as HIV-1, HBV, HCV 
and influenza, or, conversely, to trigger 
autoimmune disease. 
Although new quantitative information 
on the extent of T-cell cross-reactivity has 
recently come to light (3, 5, 9), the molecular 
rules that determine this important facet of 
cellular adaptive immunity remain unclear. 
Understanding TCR binding degeneracy and the 
ensuing T-cell cross-reactivity it enables is of 
emerging importance given the increasing use of 
T-cell therapies using modified TCRs, one of 
which has already demonstrated the dangers of 
unintentional T-cell cross-reactivity with self-
ligands (10–12). Currently, there are few 
examples of TCR-pMHC complex structures for 
which the cross-reactivity profiles of the 
corresponding T-cell clone have also been 
determined (3, 13, 14). In this study, we 
demonstrated that an insulin-reactive human 
CD8+ T-cell clone (1E6) could recognize 
upwards of 1 million unique peptide ligands. 
The structure of the 1E6 TCR with its cognate 
ligand revealed a focused TCR-peptide binding 
mode, with the interaction of only two TCR 
residues and two adjacent peptide residues 
accounting for the majority of the binding 
interface. We speculated that this focussed 
binding might enable the 1E6 TCR to tolerate 
changes outside of the core motif, mediating the 
high level of degeneracy. In support of this, 
another study recently demonstrated that a high 
level of cross-reactivity was mediated by a 
similar focused TCR-peptide binding mode by a 
MHC class II restricted TCR (13). However, 
whether TCRs must exhibit a focussed peptide 
mode in order to cross-react remains unclear. 
This is an important question because, unlike the 
two examples of focused TCR-peptide binding 
mentioned above, most TCRs that have been 
studied structurally to date make more 
comprehensive interactions with the pMHC 
surface. Thus, whether a ‘typical’ TCR binding 
mode can underpin T-cell cross-reactivity 
remains unknown.  
Here, we used a well-characterized 
CD8+ T-cell clone (ILA1) (15), that responds to 
residues 540 to 548 (sequence ILAKFLHWL) of 
hTERT to further investigate the structural basis 
of TCR degeneracy. We have previously 
characterized a limited number of altered peptide 
ligands (APLs) for the ILA1 T-cell clone that 
exhibit different potencies in terms of T-cell 
activation (9, 15), corresponding to a wide range 
of binding affinities with the ILA1 TCR (15–17). 
These previous findings clearly demonstrate that 
the ILA1 T-cell clone can recognize multiple 
different peptide ligands. Here, we solved the 
structure of the ILA1 TCR in complex with 
HLA-A*0201-ILAKFLHWL (A2-ILA) and 
several previously defined APLs. Combined 
with biophysical analysis, we demonstrate the 
molecular mechanism for antigen discrimination 
by the ILA1 TCR, and model the mode of cross-
reactivity with these APLs. In addition, we used 
our previously published peptide sampling 
approach (3) to estimate the number of pMHCI 
molecules that could be recognized by the ILA1 
TCR. These data offer novel insight into the 
molecular factors that determine T-cell cross-
reactivity, extending our understanding of the 
nature of T-cell antigen discrimination. 
 
RESULTS 
The ILA1 TCR makes a broad contact 
network with A2-ILA - We solved the structure 
of the ILA1 TCR-A2-ILA complex at 2.8 Å in 
space group P 1 21 1, with crystallographic 
Rwork/Rfree ratios within accepted limits as shown 
by the theoretically expected distribution (18) 
(Table 1). The electron density was high quality 
throughout, represented by an omit map analysis 
of the ILA peptide (Figure 1A). The ILA1 TCR 
employed a canonical binding mode to engage 
A2-ILA (Figure 1A) with a buried surface area 
(2507.2Å2) and surface complementarity (TCR-
pMHC = 0.641) within the normal range (Table 
2) (1). The TCR α-chain was orientated over the 
MHCI α1-helices and the TCR β-chain over the 
MHCI α2 helices (Figure 1B), positioning the 
CDR loops of the ILA1 TCR over the central 
portion of the peptide, enabling contacts with 4 
of the 9 peptide residues (Figure 1C). Peptide 
residues Lys4 and Trp8 engaged in a complex 
network of contacts with the TCR CDR1/3α 
loops and CDR1/3β loops respectively, 
contributing 39 out of the 49 total peptide 
contacts (Table 2). Binding to Lys4 involved a 
tight ball-and-socket interaction with 7 TCR 
residues, whereas contacts with Trp8 were less 
restrictive, involving only TCRβ-chain residues 
Glu30 and Gln96 (Table 3, Figure 1C). The 49 
TCR interactions with peptide were supported 
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by 58 contacts with MHC involving 12 TCR α-
chain residues and 4 TCR β-chain residues 
(Figure 1D), contributing to the slightly TCR α-
chain skewed binding mode (α- 58%, β- 42% of 
total contacts). Notably, the TCR α-chain residue 
Arg68 in the framework region loop (outside of 
the traditional CDR loops) formed two salt-
bridges with MHC residue Glu166, and all of the 
MHC restriction triad residues (Arg65, Ala69 
and Gln155) (19) interacted with the ILA1 TCR 
(Table 3).  
We have previously shown that the 
ILA1 TCR binds with a moderate/weak affinity 
(KD = 34µM) to A2-ILA (20), consistent with 
the observation that TCRs specific for self 
pMHCIs usually bind at the lower end of the 
TCR-pMHC affinity scale (21, 22). We 
performed a thermodynamic analysis of the 
ILA1 TCR-A2-ILA interaction by measuring 
binding using SPR at a range of temperatures (5-
37°C) (Figure 2A). These analyses 
demonstrated that the weak affinity was not 
temperature-dependent, ranging from KD = 34 
µM (25°C) to 74	   µM (5°C). At physiological 
temperature (37°C), the affinity was in the 
middle of this range (KD = 48 µM). The 
energetic analysis (Figure 2B) revealed that the 
ILA1 TCR-A2-ILA interaction was driven 
entropically (TΔS = 5.86 kcal/mol), with only a 
minor change in enthalpy (ΔH = –0.16 kcal/mol). 
These values indicate almost no net loss, or gain, 
in electrostatic interactions during complex 
formation, indicative of structural re-ordering of 
the TCR and/or pMHC when binding. The 
entropic contribution suggested that ordered 
water molecules are squeezed out at the interface 
as the TCR and pMHC engage. Overall, these 
analyses demonstrated that the ILA1 TCR 
utilizes a relatively broad binding mode, 
contacting spatially distant regions on the 
peptide and involving 21 different TCR residues 
contacting 17 A2-ILA residues (4 peptide, 13 
MHC) contributing to an entropically driven, 
moderate-to-weak affinity interaction. 
Altered peptide ligands (APLs) guide 
ILA1 antigen recognition through structural 
alterations in peptide conformation - We have 
previously characterized a number of APLs that 
alter the T-cell activation profile and TCR 
binding affinity of the ILA1 T-cell clone (9, 15, 
16). To investigate how these ligands adjust 
TCR interactions to tune affinity, we solved the 
structure of four APLs (A2-ILA3G8R: 
ILGKFLHRL, A2-ILA3G: ILGKFLHWL, A2-
ILA8T: ILAKFLHTL, A2-ILA8E: 
ILAKFLHEL), included our previously 
published APL structure (A2-ILA8R: 
ILAKFLHRL) (23), and used the ILA1-A2-ILA 
complex as a model. The electron density was 
high quality throughout, represented by an omit 
map analysis of the ILA peptide variants (Figure 
3A-D) and B-factor analysis indicated that there 
were no major differences in peptide mobility 
across the peptide variants (Figure 3E-J). 
Thermal stability analysis demonstrated that 
most of the APLs had a similar apparent Tm 
value (the term ‘apparent Tm’ is used here 
because the protein irreversibly aggregates at 
high temperature) of around 55°C, with 
extremes in the range of 50°C to 61°C (Figure 
4). These similar stabilities are consistent with 
our previous observation that all these APLs 
bind equally to HLA-A2 on the cell surface (15). 
As we have shown previously in other systems 
(24), apparent Tm values correlated poorly with 
antigen potency (for instance A2-ILA3G had the 
lowest apparent Tm value, but was a potent 
activator of the ILA1 T-cell clone), suggesting 
that different pMHC cell surface expression 
levels were a minor factor in T-cell recognition. 
The A2-ILA3G structure was determined at 2.7 
Å resolution and the other APL structures were 
determined at resolutions between at 1.9 Å-1.8 Å, 
with crystallographic Rwork/Rfree ratios within 
accepted limits as shown by the theoretically 
expected distribution (18) (Table 1). The overall 
conformation of A2-ILA3G8R, A2-ILA3G and 
A2-ILA8R were virtually identical to A2-ILA 
(Figure 5A-D), with Lys4, Leu6, and Trp8 
pointing up and away from the MHC binding 
groove and Leu2, Phe5, His7, and Leu9 acting as 
primary and secondary anchors, indicating that a 
molecular mimicry mechanism underpins ILA1 
TCR recognition of these APLs. In contrast, in 
the A2-ILA8T and A2-ILA8E structures, peptide 
residues 5-7 were flipped so that Leu6 acted as a 
secondary anchor and Phe5 and His7 were in 
more solvent-exposed positions (Figure 5E-F). 
In both peptide variants, the mutated residue was 
at position 8, distal from this structural 
rearrangement. Closer inspection of the 
structures did not reveal an obvious mechanism 
for this indirect effect on peptide conformation.  
We next explored the binding affinity of 
the ILA1 TCR for the APLs included in this 
study using previously published (9, 15, 16) and 
new data (Figure 6A-E). Despite the relatively 
weak affinity between the ILA1 TCR and the 
natural A2-ILA ligand (KD = 34 µM), the ILA1 
TCR could recognize A2-ILA3G8R and A2-
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ILA3G with anti-viral-like affinities (KD = 1 µM 
and 3.7 µM respectively). Both of these ligands 
included substitution of peptide residue 3 from 
Ala to Gly, a substitution that was clearly 
indicated in our previously published unbiased 
combinatorial peptide library (CPL) screening 
using the ILA1 T-cell clone (9). Structural 
modelling of the ILA1 TCR with these ligands 
indicated that interaction with the N-terminal 
portion of the peptide was likely to be very 
similar for both ligands (Figure 6F&G). 
However, for A2-ILA3G8R, a major re-
orientation of TCR β-chain residue Gln96 would 
be required in order to tolerate Arg at position 8 
in the peptide. For both of these ligands, the 
extra flexibility, afforded at the N-terminus of 
the peptide by the substitution of Gly compared 
to Ala, may enable the ILA1 TCR to establish 
enhanced contacts with peptide residue Lys4. 
This represents a likely mechanism for the 
stronger affinity, supported further by the 
observation that all of the other APLs that did 
not include Gly at position 3 were bound by 
ILA1 with weaker affinity compared to the 
ILA1-A2-ILA interaction (Figure 6C-E). 
Structural modelling of ILA1 in complex with 
A2-ILA8R (Figure 6H) revealed the same 
potential for steric hindrance between the TCR 
β-chain residues Glu30 and Gln96, but without 
the compensatory substitution at position 3. The 
structural rearrangement that would be required 
for ILA1 to bind to A2-ILA8R (KD = 151 µM) 
was reflected by a much weaker affinity 
compared to ILA1-A2-ILA (KD = 34 µM). Both 
A2-ILA8T and A2-ILA8E ligands underwent a 
conformational transition compared to the other 
APLs (Figure 5). Modelling demonstrated that 
this alteration could lead to a steric conflict 
between TCR β-chain residue Gln96 and the C-
terminal residues of the peptide (Figure 6I&J). 
However, the position of peptide residue Phe5 in 
A2-ILA8T may allow for compensatory 
interactions with TCR α-chain residues Asp91 
and Tyr98, not present with A2-ILA8E. 
Furthermore, the smaller Thr8 side chain in A2-
ILA8T, compared to Glu8 in A2-ILA-8E, would 
require smaller modifications in TCR docking. 
Taken together, these structural distinctions may 
explain the extremely weak affinity observed for 
ILA1 binding to A2-ILA8E compared to A2-
ILA8T (KD >500 mM and 28 µM, respectively).  
Quantification of ILA1 TCR degeneracy  
- Our previous investigations have demonstrated 
that even single residue substitutions outside of 
the two main peptide interaction zones (Lys4 
and Trp8) could have a substantial impact on the 
ILA1 TCR-A2-ILA complex, reflected by the 
different binding affinities and antigen potencies 
shown here and published previously (9, 15, 16). 
This binding mode is in stark contrast to the 
focused TCR-peptide binding mode of the 
highly cross-reactive auto-reactive T-cell clone 
(1E6) (3, 6, 14), known to mediate β-cell 
destruction in patients with type 1 diabetes (25, 
26). We next generated a degeneracy curve for 
the ILA1 TCR using our previously described 
approach that quantifies TCR cross-reactivity (3).  
CPL scan data were used to design four 
different motif-restricted peptide sets (I: 
xLGxxxxRL (total set size 195); II: xLxKFLxxL 
(total set size 194); III: 
xLG{K/L}F{L/I}{M/F/Y/N/H}{R/T/Y/K/S/F/H
/I/L/M/Q/V/G/N}{L/V} (total set size 10640); 
and, IV: 
{A/I/L/M/P/Q/W}L{G/A}{K/L}F{L/I}{N/H} 
{F/K/N/Q/T/Y}{L/V} (total set size 1344); 
where x denotes any of the 19 proteogenic 
amino acids excluding cysteine). Between 19 
and 30 peptides were sampled at random from 
each of these motif-restricted peptides cohorts. 
In addition, we performed importance sampling 
where 20 peptides were sampled from an 
effective sample size of 1.5 × 107. The pEC50 for 
each peptide was estimated by simultaneous 
curve fitting (Figures 7) and these values were 
used to construct a degeneracy curve for the 
ILA1 TCR (Figure 8A). These analyses 
indicated that ILA1 could recognise ~2 × 103 
peptides with a functional sensitivity at least as 
high as 1/10th the functional sensitivity of the 
optimal agonist. At two orders of magnitude 
from the optimum (i.e. peptides ranging 
from1/100th of the optimal agonist to the optimal 
agonist) ~4 × 104 peptides could be recognised 
by the ILA1 T-cell clone.  
This analysis suggests that the ILA1 
TCR can cross-react with a diverse peptide 
universe. Although smaller than the estimated 
number of peptides recognised by the 1E6 T-cell 
clone (~106), it should be noted that 1E6 
recognises a 10-mer peptide, whereas ILA1 
recognises a 9-mer. Thus, the peptide universe 
under consideration for 1E6 is 20 times larger 
than that for ILA1. Although it is unknown how 
this difference in peptide length affects the 
comparison between the two degeneracy 
profiles, this difference may partly explain why 
ILA1 appears to be less cross-reactive than 1E6. 
This analysis also demonstrated a different 
pattern of cross-reactivity between the 1E6 and 
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ILA1 T-cell clones that was consistent with the 
respective binding modes of their TCRs. The 
1E6 T-cell clone could recognise a large number 
of sub-libraries (46 in total) outside of the 
central binding zone (residues 4-6) (Figure 8B). 
In contrast, the ILA1 T-cell clone was generally 
more sensitive across the peptide backbone, 
reflecting a more globally coordinated 
interaction between the ILA1 TCR and the 
antigenic peptide (Figure 8C). Taken together, 
these results are broadly consistent with the idea 
that different modes of TCR binding (i.e. TCRs 
that focus on a minimal peptide motif compared 
to TCRs that make contacts across the peptide 
backbone) can enable T-cell cross-reactivity, 
adding further support to the general idea that T-
cells must be cross-reactive to fully protect us 
against a highly variable pathogen universe 
(reviewed in (8)).  
 
DISCUSSION 
In order to mount effective immune 
responses in the face of a diverse antigenic 
milieu, using a limited set of TCRs (estimated 
~25 million distinct clonotypes in an individual), 
each T-cell must be able to interact productively 
with a vast array of different antigens (2, 8). 
Indeed, recent experimental evidence supports 
this notion, including our own study 
demonstrating that a single T-cell clone can 
recognize over 1 million different peptides at 
physiologically relevant concentrations (3). 
However, structural investigations of TCR-
pMHC interactions have demonstrated that the 
TCR can establish a distinct and highly specific 
interaction with both peptide and MHC. In 
keeping with such specificity of binding 
requirements, even single mutations at key 
residues in the TCR, peptide, or MHC that are 
involved in the binding interface have been 
shown to abrogate antigen recognition (27–31). 
The importance of T-cell cross-reactivity is 
manifest not only in effective immune 
surveillance (2, 8), but also in auto-reactivity 
(32) and the design of therapeutics (10, 11). 
Structural rules must therefore exist that allow 
cross-reactivity to take place; here, we report 
early steps toward deconstructing these rules. 
We investigated a TCR isolated from 
ILA1, a well-characterized HLA-A*0201-
restricted, telomerase-specific, CD8+ T-cell 
clone. Our previous work has shown that ILA1 
cross-reacts with an array of APLs with different 
potencies, tuned by the CD8 co-receptor, and 
that antigen ‘potency’ generally correlates 
directly with the affinity of TCR binding (9, 15). 
Here, we solved the complex structure of the 
ILA1 TCR with the natural index ligand (A2-
ILA) and used the structures of a number of 
unligated APLs to model the mode of APL 
recognition and determine the structural basis for 
ILA1 cross-reactivity.  
We have previously demonstrated that 
the ILA1 T-cell clone is particularly sensitive to 
APLs with modifications at peptide residues 3 
and 8. The unligated structures of five APLs 
with alterations in these positions demonstrated 
that the overall conformation of the Cα peptide 
backbone could be altered by introduction of Thr 
or Glu at position 8, possibly explaining the 
weaker binding affinity between ILA1 and A2-
ILA8R and A2-ILA8E. In contrast, substitution 
of Ala to Gly at peptide residue 3 enhanced 
recognition, and Gly at this position was 
strongly recognised in combinatorial peptide 
library screens (9). Our structural analysis 
indicated that the surmised extra flexibility 
afforded to the N-terminus of the peptide 
mediated by substitution at position 3 with Gly 
would likely enable more favourable interactions 
with Lys4, which made a network of contacts 
with the ILA1 TCR through a ‘ball-and-socket’-
like interaction. In fact, substitution at position 3 
with Gly could override the negative impact of 
modifications to peptide residue 8, revealed by 
the enhanced binding affinity of the ILA1-A2-
ILA3G8R interaction (KD = 1 µM) compared to 
the index peptide (KD = 34 µM) and ILA8R (KD 
= 151 µM). Our structural analysis demonstrated 
that, again, even single peptide substitutions 
outside of the main interaction interface could 
have a substantial impact on TCR binding 
affinity and T-cell antigen potency, consistent 
with our previous findings (9, 15, 16). These 
observations add further evidence to our recent 
findings (19, 33–36) that peptide presentation by 
MHC-I can be dynamic and difficult to predict. 
Recent reports have demonstrated that 
TCRs using a focused TCR-peptide binding 
mode can be highly cross-reactive (37, 38). 
However, this binding mode is not representative 
of most TCRs described in the literature. Indeed, 
on average TCR-peptide binding is spread out 
over ~60% of the peptide backbone for MHCI-
restricted epitopes, often including contacts with 
both the N- and C-terminal regions of the 
peptide (1, 39). This interconnected binding 
network between the TCR and the peptide may 
not allow a high degree of cross-reactivity 
because most peptide modifications could 
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impact on binding. Unlike the focused TCR-
peptide binding mode utilised by the 1E6 (37) 
and 42F3 (40) TCRs, the ILA1 TCR employed  
a more representative binding mode to A2-ILA. 
This was reflected by a larger BSA value 
(2540Å for ILA1 compared to 1640Å for 1E6) 
and a binding motif that included contacts spread 
out over peptide residues 4-8.  Thus, we 
explored the consequences of the ILA1 TCR 
binding mode on ILA1 T-cell cross-reactivity 
using our previously published methodology (3). 
Despite the broader binding mode utilised by the 
ILA1 TCR, the ILA1 T-cell clone was still able 
to recognise ~4 × 104 peptides with equal or 
greater sensitivity compared to the index 
peptide, and many more at lower potency. These 
data suggest that although the mode of TCR 
binding is very likely to tune T-cell cross-
reactivity to some degree, the ability of T-cells 
to recognise a vast array of different peptides is 
likely to be commonplace. 
In summary, we demonstrate that the 
interaction between a TCR from a human CD8+ 
T-cell clone that recognises a peptide sequence 
from an important tumour antigen contacts the 
peptide at spatially distant sites along the peptide 
backbone. The affinity of this TCR can be tuned 
by various peptide modifications through both 
direct and indirect effects, demonstrating the 
dynamic nature of the interaction between TCR, 
peptide and MHC. Even though the ILA1 T-cell 
clone was sensitive to modifications along the 
peptide backbone, consistent with its broad 
binding interface, it was still able to cross-react 
with a vast array of different peptides. These 
data demonstrate that focused TCR-peptide 
binding is not a requirement for T-cell 
degeneracy. Indeed, a broader binding mode, as 
observed in most TCR-pMHC structures 
reported to date, is also likely to facilitate T-cell 
cross-reactivity. These results have important 
implications for immune surveillance, i.e. how a 
limited set of TCRs can recognize all potential 
antigens variants, and the complex mechanisms 
that may lead to auto-reactivity mediated by 
molecular mimicry. 
 
EXPERIMENTAL PROCEEDURES 
T-Cells and target cells - The ILA1 
CD8+ T-cell clone is specific for the HLA 
A*0201 restricted human telomerase reverse 
transcriptase-derived epitope ILAKFLHWL 
(residues 540–548) (41), and the 1E6 T-cell 
clone is specific for the human leukocyte antigen 
HLA A*0201 restricted autoantigen PPI 
(preproinsulin) epitope ALWGPDPAAA 
(residues 15 - 24) (25). CD8+ T-cell clones were 
maintained in RPMI 1640 (Life Technologies, 
Rockville, MD) containing 100 U/ml penicillin 
(Life Technologies), 100 mg/ml streptomycin 
(Life Technologies), 2 mM L-glutamine (Life 
Technologies), and 10% heat inactivated FCS 
(Life Technologies) (R10) supplemented with 
2.5% Cellkines (Helvetica Healthcare, Geneva, 
Switzerland), 200IU/ml IL-2 (PeproTech, Rocky 
Hill, NJ) and 25 ng/ml IL-15 (PeproTech). 
Hmy.2 C1R B-cells expressing full-length HLA 
A*0201 were generated as described previously 
(42). 
Protein expression, refolding and 
purification - The ILA1 TCR, HLA-A*0201 α 
chain and human β2m chain sequences were 
generated as previously described (20), and 
cloned into separate pGMT7 expression 
plasmids under the control of the T7 promoter. 
The ILA1 TCR and HLA-A*0201 in complex 
with various different peptide variants (as 
indicated) were refolded and purified as 
described previously (14). Biotinylated pMHCI 
was prepared as previously described (43).  
pMHC stability assays - Thermal 
stability of the HLA-A*0201-peptid complexes 
was assessed by circular dichroism spectroscopy 
monitoring the change in ellipticities at 218 nm 
upon heating as described (33). Briefly, samples 
were prepared in PBS at a concentration of 
~3µM.and measured in 0.1-cm quartz cells. 
Melting curves were analyzed assuming a two-
state trimer-to-monomer transition from the 
native to unfolded conformation and fitted as 
described (44). As all protein complexes 
aggregated to various degrees upon unfolding, 
the ellipticity of the unfolded state was set as a 
constant of -1.35 M-1 cm-1 (45). 
 Surface Plasmon Resonance Analysis  - 
Binding analysis was performed in duplicate 
using a BIAcoreT200™ equipped with a CM5 
sensor chip as previously described (46). 
Approximately 200-500 RU of HLA-A*0201-
ILGKFLHRL or HLA-A*0201-
ILAKFLHRLpeptide complex was attached to 
the CM5 sensor chip at a slow flow-rate of 10 
µL/min to ensure uniform distribution on the 
chip surface. HLA-A*0201-ILAKFLHWL was 
used as a positive control as the binding affinity 
with the ILA1 TCR has been published 
previously (15, 20). The ILA1 TCR was purified 
and concentrated to ~300 µM on the same day of 
surface plasmon resonance (SPR) analysis. For 
equilibrium analysis, 10 serial dilutions were 
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prepared in duplicate for each sample and 
injected over the relevant sensor chips at 25°C. 
TCR was injected over the chip surface using 
kinetic injections at a flow rate of 45 µL/min 
using HLA-A*0201-ALWGPDPAAA as a 
negative control surface on flow cell 1. Results 
were analyzed using BIAevaluation 3.1, Excel 
and Origin 6.0 software. The equilibrium 
dissociation constant (KD) values were 
calculated assuming a 1:1 interaction by plotting 
specific equilibrium-binding responses against 
protein concentrations followed by non-linear 
least squares fitting of the Langmuir binding 
equation. For kinetics analysis, the kon and koff 
values were calculated assuming 1:1 Langmuir 
binding and the data were analyzed using a 
global fit algorithm (BIAevaluation 3.1™). 
Crystal structure determination - All 
protein crystals were grown at 18°C by vapour 
diffusion via the sitting drop technique. 200 nL 
of each pMHCI (10 mg/ml) in crystallization 
buffer (10 mM Tris pH 8.1 and 10 mM NaCl) 
was added to 200 nL of reservoir solution. ILA1-
HLA-A*0201-ILAKFLHWL (ILA1-A2-ILA) 
and HLA-A*0201-ILAKFLHTL (A2-ILA8T) 
crystals were grown in 0.2 M ammonium 
sulphate, 0.1 M HEPES pH 7, 20% PEG 8000 
(47); HLA-A*0201-ILGKFLHRL (A2-
ILA3G8R) crystals were grown in 0.2 M 
ammonium sulphate, 0.1 M Tris pH 7.5, 25% 
PEG 8000 (47); HLA-A*0201-ILGKFLHWL 
(A2-ILA3G) crystals were grown in 0.2 M 
ammonium sulphate, 0.1 M MES pH 7, 15% 
PEG 8000;  HLA-A*0201-ILAKFLHEL (A2-
ILA8E) crystals were grown in 0.2 M 
ammonium sulphate, 0.1 M MES pH 7, 25% 
PEG 8000 (47).  Crystallization screens were 
conducted using an Art-Robbins Phoenix 
dispensing robot (Alpha Biotech Ltd, UK) and 
data were collected at 100 K at the Diamond 
Light Source (DLS), Oxfordshire, UK at a 
wavelength of 0.98 Å using an ADSC Q315 
CCD detector. Reflection intensities were 
estimated using XIA2 (48) and the data were 
analyzed with SCALA and the CCP4 package 
(49). Structures were solved with molecular 
replacement using PHASER (50). Sequences 
were adjusted with COOT (51) and the models 
refined with REFMAC5. Graphical 
representations were prepared with PYMOL (52). 
The reflection data and final model coordinates 
were deposited with the PDB database (ILA1-
A2-ILA PDB: 5C60, A2-ILA3G8R PDB: 5C61, 
A2-ILA3G PDB: 5C62, A2-ILA8T PDB: 5C63, 
A2-ILA8E PDB: 5C64). 
CD8+T-cell effector function assays: 
MIP1β ELISA - 6 × 104 C1R-A2 cells were 
incubated with peptide at various concentrations 
in duplicate for 2 hours at 37ºC. Subsequently, 3 
× 104 ILA1 CD8+ T-cells were added and the 
assay was incubated overnight at 37ºC. The 
supernatant was harvested and assayed for 
MIP1β by ELISA according to the 
manufacturer's instructions (R&D Systems). 
Functional sensitivity of individual peptides was 
expressed as the pEC50 of each peptide, which is 
defined as –1 × the base 10 logarithm (p) of the 
50% efficacy concentration (EC50). 
Quantification of ILA1 TCR degeneracy 
- The degeneracy of the ILA1 TCR was 
estimated as described previously (3). Briefly, 
the degeneracy at ω, defined as the number of 
peptides whose functional sensitivity is at least 
as large as ω was estimated directly using 
importance sampling based on the combinatorial 
peptide library scan, and bounded below by 
sampling from motif-based subsets of the 
peptide universe. The degeneracy is reported by 
plotting this quantity as a function of ω, where 
the functional sensitivity ω was scaled relative to 
a clone-specific reference peptide (the “index”). 
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Figure Legends 
 
Figure 1. The ILA1 TCR uses a broad binding mode to engage A2-ILA. (A) The overall 
binding mode of ILA1 TCR (blue and cyan cartoon – CDR loops shown in multi-colored 
cartoon) in complex with A2-ILA (grey cartoon and orange sticks). The box shows the 
observed map (top) at 1.0 σ and an omit maps (below) in which the model was refined in the 
absence of the ILA peptide with difference density is contoured at 3.0 σ; positive contours are 
shown in green, and negative contours are red. (B) Position of the ILA1 TCR CDR loops 
(multi-coloured sticks) with the ILA peptide (orange sticks) is shown in the HLA-A*0201 
binding groove (grey surface). The crossing angle of the ILA1 TCR (black line) was 
calculated using previously published parameters (39). Briefly, this crossing angle represents 
the angle between a best- fit straight line through the Cα atoms from the two MHC helices, 
and a line that links the disulphide bond in the TCR α chain variable region to the disulphide 
bond in the TCR β chain variable region. (C) Interaction between residues in the ILA1 TCR 
CDR loops (multi-colored sticks) and the ILA1 peptide (orange sticks) with the MHCα1 helix 
shown as grey cartoon. (D) The ILA1 TCR residues in the CDR loops that contact the MHC 
surface are shown in multicolored cartoon and surface with the MHC binding groove shown 
in grey cartoon and surface. CDR loops are colored as follows throughout: CDR1α – red, 
CDR2α – green, CDR3α – blue, CDR1β – yellow, CDR2β  
 
Figure 2. Thermodynamic analysis of the ILA1 TCR with A2-ILA. (A) Eight serial 
dilutions of the ILA1 TCR were injected, in duplicate, over A2-ILA at 5°C, 13°C, 21°C, 25°C, 
29°C, and 37°C. The equilibrium binding constants (KD) were calculated using a nonlinear 
curve fit (y= (P1x)/P2 + x)) and kinetic and affinity parameters are shown in the table. (B) The 
binding free energies, ΔG° (ΔG° = RTlnKD), were plotted against temperature (K) using non-
linear regression to fit the three-parameters van ’t Hoff equation, (RT ln KD = ΔH° –TΔS° + 
ΔCp°(T-T0) – TΔCp° ln (T/T0) with T0=298 K). 
– purple, andCDR3β – cyan. 
 
Figure 3. Density plot, omit map and B-factor analysis of ILA1 peptide variants. Above: 
The observed map at 1.0 σ is shown. Below: omit maps are shown, in which the model was 
refined in the absence of the ILA peptide variants, with difference density contoured at 3.0 σ; 
positive contours are shown in green, and negative contours are red. (A) A2-ILGKFLHRL 
(purple sticks). (B) A2-ILGKFLHWL (green sticks). (C) A2-ILAKFLHTL (sand sticks). (D) 
A2-ILAKFLHEL (black sticks). A2-ILAKFLHRL was solved previously (23). (E-J) Each 
APL is coloured by B-factor, with light blue representing a low B-factor, and red representing 
a high B-factor. The conformation of each APL (sticks) with arrows indicating the direction 
of each residue in the peptide (solvent exposed, MHC anchor, or in between) with the 
MHCα1 helix shown as grey cartoon. Residues in red indicate differences from the index 
sequence. Up arrow indicates solvent exposed, down arrow indicates anchor position, no 
arrow indicates an intermediate position. (E) A2-ILAKFLHWL. (F) A2-ILGKFLHRL. (G) 
A2-ILGKFLHWL. (H) A2-ILAKFLHRL. (I) A2-ILAKFLHTL. (J) A2-ILAKFLHEL. 
 
Figure 4: Stability of HLA-A2-ILA variants using circular dichroism. (A). CD thermal 
denaturation curves recorded at 218nm are shown for selected pHLAI samples. Dots 
represent measured values fitted assuming a 2-state trimer-to-monomer transition (dashed 
lines) as described in Materials and Methods. (B). Bar graphs of the thermal stability with 
respect to melting temperature (upper) and van 't Hoff's enthalpy of unfolding (lower panel).  
Figure 5. Structural analysis of ILA1 TCR ligands. Conformation of each APL (sticks) 
demonstrating the direction of each residue in the peptide (solvent exposed, MHC anchor, or 
in between) with the MHCα1 helix shown as grey cartoon. Residues in red indicate 
differences from the index sequence. Up arrow indicates solvent exposed, down arrow 
indicates anchor position, no arrow indicates an intermediate position. (A) A2-ILAKFLHWL 
(orange sticks). (B) A2-ILGKFLHRL (purple sticks). (C) A2-ILGKFLHWL (green sticks). 
(D) A2-ILAKFLHRL (brown sticks), reproduced from (23). (E) A2-ILAKFLHTL (sand 
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sticks). (F) A2-ILAKFLHEL (black sticks). The circled residues in (E) and (F) face in 
different directions as compared to the index telomerase sequence (ILAKFLHWL) in (A).  
 
Figure 6. Equilibrium binding analysis and structural modelling of the ILA1 TCR 
interaction with the APLs. Binding affinity of the ILA1 TCR interaction with different 
APLs at 25°C. Eight serial dilutions of the ILA1TCR were injected over A2-ILA8R and A2-
ILA3G8R and representative data from 3 independent experiments are plotted after deducting 
binding to a control sample (HLA-A*0201-ALWGPDPAAA). The equilibrium binding 
constants (KD) were calculated using a nonlinear curve fit (y= (P1x)/P2 + x)). (A) ILA1-A2-
ILA3G8R (B) ILA1-A2-ILA3G (reproduced from (15)), (C) ILA1-A2-ILA8R, (D) ILA1-A2-
ILA8T (reproduced from (15)), (E) ILA1-A2-ILA8E (reproduced from (15)). The ILA1 TCR 
was modelled with each of APL ligands by aligning the uncomplexed APLs with A2-ILA in 
the ILA1-A2-ILA complex structure (HLA-A*0101 α1 helix shown in gray cartoon in panels 
F-J). Potential steric clashes are highlighted in red circles. (F) A2-ILA3G8R (peptide in 
purple) showing modelled positions of the TCR CDR3α and β loops (blue and cyan, 
respectively) (G) A2-ILA3G (peptide in green) superposed with the A2-ILA peptide (orange), 
(H) A2-ILA8R (peptide in brown) showing modelled positions of the TCR CDR1, 2 and 3 α 
β loops (yellow, pink and cyan, respectively), (I) A2-ILA8T (peptide in sand) showing 
modelled positions of the TCR CDR3α and β loops (blue and cyan, respectively) and (J) 
ILA1-A2-ILA8E (peptide in black) showing modelled positions of the TCR CDR3α and β 
loops (blue and cyan, respectively). 
 
Figure 7: pEC50 values for all peptide ligands tested. Simultaneous curve fitting was used 
to estimate functional sensitivity measured as pEC50 for peptides sampled from: I.  
xLGxxxxRL (set size 195; 30 peptides sampled at random); II. xLxKFLxxL (set size 194; 30 
peptides sampled at random); III. xLG{K/L}F{L/I} 
{M/F/Y/N/H}{R/T/Y/K/S/F/H/I/L/M/Q/V/G/N }{L/V} (set size 10640; 30 peptides sampled 
at random); IV. {A/I/L/M/P/Q/W}L{G/A}{K/L}F{L/I}{N/H} {F/K/N/Q/T/Y}{L/V}  and V. 
replicate of a biased sampling each set (20 peptides sampled from an effective sample size of 
1.5 × 107). 
 
Figure 8. TCR binding mode contributes to T-cell cross-reactivity. (A) Peptide 
recognition degeneracy for ILA1. The degeneracy curve plots the estimated number of 
peptides that have a functional sensitivity at least as strong as abscissa. The highest value of 
abscissa corresponds to inferred functional sensitivity of optimal peptide, whereas the lowest 
value of abscissa lies 10 orders of magnitude below this optimum. Bias: degeneracy curve 
based on agonist-biased importance sampling. Curves I–IV are motif-based, i.e., sampled 
from subsets of the entire peptide universe, and therefore lie below the degeneracy curve. I: 
xLGxxxxRL (set size 195; 30 peptides sampled at random); II: xLxKFLxxL (set size 194; 30 
peptides sampled at random); 
III:xLG{K/L}F{L/I}{M/F/Y/N/H}{R/T/Y/K/S/F/H/I/L/M/Q/V/G/N}{L/V} (set size 
10640;30 peptides sampled at random); IV: {A/I/L/M/P/Q/W}L{G/A}{K/L}F{L/I}{N/H} 
{F/K/N/Q/T/Y}{L/V} (set size 1344; 19peptides sampled at random); x denotes any of the 19 
amino acids excluding cysteine and y denotes any of the 20 amino acids. Cross-reactivity of 
the 1E6 (B) and ILA1 (C) CD8+ T-cell clones estimated by the number of residues recognized 
in a combinatorial peptide library screen generating responses over >0.5ng/mL MIP-1β. Bars 
that represent positions in the peptide that are anchor residues are colored grey. Bars that 
represent residues that are main contact sites for each respective TCR are colored red.  
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Tables: 
 
Table 1. Data collection and structure refinement statistics 
 
  ILA1-A2-ILA A2-ILA3G8R A2-ILA3G A2-ILA8T  A2-ILA8E 
Data collection           
PDB code 5C60 5C61 5C62 5C63 5C64 
Space group P 1 21 1 P 21 21 21 P 21 21 21 P 1 21 1 P 21 21 21 
Beamline DLS I24 DLS I04 DLS I02 DLS I04 DLS I02 
 
Cell dimensions 
          
a, 
b, 
c (Å) 
93.2,  
48.7,  
118.1 
49.2,  
74.9,  
125.8 
119.4,  
169.6,  
47.1 
53.34,  
81.44,  
56.77 
45.7,  
119.0,  
170.3 
α,  
β,  
γ  (°) 
90,  
108.2,  
90 
90,  
90,  
90 
90,  
90,  
90 
90,  
113.5,  
90 
90,  
90,  
90 
Resolution Maximum (Å) 2.81  
(2.88 - 2.81) 
1.77  
(1.82 - 1.77) 
2.71 
(2.78 - 2.71) 
2.27 
(2.33 – 2.27) 
1.88  
(1.93 -1.88) 
Rmerge (%) 0.100 (0.73) 0.105 (0.718) 0.105 (.831) 0.086 (0.632) 0.098 
(0.621) 
Total Measurements 91,454    
(6,913) 
332,927 
(22,417) 
195,005 
(13,976) 
74,664 
(5,741) 
545,975 
(42,439) 
Unique reflections 25,031  
(1,865) 
46,011  
(3,362) 
26,894  
(1,974) 
20,523 
(1,527) 
76,630 
5,603 
I / σI 9.2 (1.9) 10.5 (2.5) 14.1 (2.3) 12.8 (1.9) 10.8 (3.2) 
CC1/2 n/a n/a 0.997 (0.714) 0.997 (0.842) 0.997 
(0.913) 
Completeness (%) 99.7 (99.8) 100 (100) 100 (100) 99.3 (98.9) 99.9 (100) 
Multiplicity 3.7 (3.7) 7.2 (6.7) 7.3(7.1) 3.5 (3.8) 7.1 (7.6) 
 
Refinement 
          
Resolution (Å) 56.11 - 2.81 48.16 - 1.77 42.39 - 2.71 48.90 – 2.27 34.06 - 1.9 
No. reflections in Work set 23,666 43,626 25,511 19,484 72,747 
No reflections in Rfree set 1,267 2,319 1,333 1,023 3,797 
Rwork/Rfree (%) 18.9/27.2 17.1/21.4 18.2/23.9 20.3/26.4 18.4/22.4 
Mean B value (Å2) 57.1 27.7 52.2 37.7 33.0 
Wilson B factor (Å2) 70.5 21.9 39.6 32.97 28.6 
Overall coord error (Å) 0.377 0.082 0.252 0.232 0.098 
R.m.s. deviations           
Bond lengths (Å) 0.017 0.019 0.013 0.019 0.019 
Bond Angles (°) 2.025 1.983 1.658 1.976 1.967 
Ramachandran Plot 
statistics 
         
Most Favoured region (%) 92.27 97.85 97.23 96.54 98.12 
Allowed Region (%) 6.38 2.15 2.77 3.19 1.88 
Outliers (%) 1.35 0 0 0.27 0 
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N.B. Figures in brackets refer to the highest resolution bin 
 
* One crystal was used for solving each structure. 
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Table 2: ILA1-A2-ILA Contact Summary 
 
 vdW (≤4 Å) H-bonds (≤3.4 Å) salt bridges (≤3.4 Å) 
MHC 58 6 2 
Peptide 49 4 1 
Peptide Lys4 20 2 1 
Peptide Trp8 19 2 0 
TCRα 62 7 3 
CDR1α 16 2 0 
CDR2α/FW 9 2 2 
CDR3α 37 3 1 
TCRα Asp97 6 2 0 
TCRα Arg68 4 0 2 
TCRβ 45 3 0 
CDR1β 13 0 0 
CDR2β 7 0 0 
CDR3β 25 3 0 
TCRβ Gln96 18 3 0 
Total contacts 107 10 3 
    
BSA(Å2) 2507.2   
SC (TCR-MHC) 0.635   
SC (TCR-p) 0.707   
SC (TCR-pMHC) 0.641   
Crossing angle (°)* 51.8   
 
BSA – buried surface area 
SC – surface complementarity 
*calculated as previously described (39) 
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Table 3: ILA1-A2-ILA contacts 
CDR 
loop 
Gene 
Usage 
TCR  
residue 
Peptide 
residue 
MHC 
 residue 
vdW 
 (≤4 Å) 
H-bonds 
 (≤3.4 Å) 
CDR1α TRAV22 Asp27Oδ2   Thr163Oγ1 4 1 
  TRAV22 Asp27Oδ1   Glu166Oε2 2 1 
  TRAV22 Ser28   Ala158 1   
  TRAV22 Val29   Gln155 4   
  TRAV22 Val29 Lys4   4   
  TRAV22 Asn30   Gln155 1   
CDR2α TRAV22 Tyr48   Glu154 1   
  TRAV22 Tyr48   Gln155 2   
  TRAV22 Ser51O   Glu154Oδ 1 1 
  TRAV22 Ser51   Arg157 1   
  TRAV22 Gln55Oε1   Glu154Oε2   1 
FWα TRAV22 Arg68NH1/NH2   Glu166Oε1/Oε2 4 2 salt bridges 
CDR3α TRAJ40 Asp91Oδ1 Lys4Nζ   3 1 salt bridge 
  TRAJ40 Ser92O Lys4Nζ   2 1 
  TRAJ40 Ala93   Lys66 1   
  TRAJ40 Ala93   Thr163 2   
  TRAJ40 Ala93 Lys4   2   
  TRAJ40 Thr94O   Lys66Nζ 3 1 
  TRAJ40 Thr94   Trp167 3   
  TRAJ40 Ser95 Lys4   4   
  TRAJ40 Gly96   Arg65 3   
  TRAJ40 Thr97O Lys4Nζ   3 1 
  TRAJ40 Tyr98   Lys66 3   
  TRAJ40 Tyr98   Ala69 2   
  TRAJ40 Tyr98 Lys4   2   
  TRAJ40 Tyr98 Leu6   4   
CDR1β TRBV6 Glu30 Trp8   13   
CDR2β TRBV6 Val50   Val152 1   
  TRBV6 Val50 Leu6   1   
  TRBV6 Val50 Trp8   1   
  TRBV6 Ile54   Gln72 4   
CDR3β TRBJ1-1 Tyr95   Lys146 5   
  TRBJ1-1 Tyr95   Ala150 2   
  TRBJ1-1 Gln96   Lys146 2   
  TRBJ1-1 Gln96Oε1   Trp147Nε1 4 1 
  TRBJ1-1 Gln96   Ala150 1   
  TRBJ1-1 Gln96   Val152 1   
  TRBJ1-1 Gln96 Leu6   2   
  TRBJ1-1 Gln96 His7   3   
  TRBJ1-1 Gln96Oε1 Trp8N/O   5 2 
N = N-nucleotide insertion 
*A 3.4Å cut-off was used for H-bonds and salt bridges and a 4Å cut-off was used for vdW.  
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Table 4: ILA1 TCR binding affinity to peptide variants	  
 
 
HLA-A*0201 ILA variant Kon M-1s-1 Koff s-1 Chi2	  for	  Kon	  &	  Koff KD µM  
HLA-A*0201-ILGKFLHRL 3x104 0.16 4.2 1±0.1 
HLA-A*0201-ILGKFLHWL (41) 1.6x104 0.05 3.6 3.7±0.2 
HLA-A*0201-ILGKFLHTL (17) 1.95x104 0.05 2.5 2.5±0.5 
HLA-A*0201-ILAKFLHYL (41) n/m n/m n/m 22.6±2.1 
HLA-A*0201-ILAKFLHWL (20) 4.5x103 0.15 4.3 34±2 
HLA-A*0201-ILAKFLHTL (41) 2.2x103 0.08 1.9 28±5 
HLA-A*0201-ILAKFLYWL (41) n/m n/m n/m 82±8 
HLA-A*0201-ILALFLHWL (16) 1.7x103 0.2 4.2 117±6 
HLA-A*0201-ILAKFLHRL n/m n/m n/m 151±8 
HLA-A*0201-ILAKYLHWL (17) 1.3x103 0.32 3.5 242±20 
HLA-A*0201-ILAKFLHEL (41) n/m n/m n/m >500 
 
n/m = kinetics were too fast to accurately measure 
KD calculated from equilibrium binding experiments 
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